Drug updated on 11/1/2023

Dosage FormTablet (oral: 200 mg, 550 mg)
Drug ClassAntibacterial
Ongoing and Completed StudiesClinicalTrials.gov


  • Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older.
  • For reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
  • Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Xifaxan (rifaximin) Prescribing Information.2022Salix Pharmaceuticals, Bridgewater, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines